Schrödinger to Present at Jefferies London Healthcare Conference
Get Alerts SDGR Hot Sheet
Join SI Premium – FREE
NEW YORK--(BUSINESS WIRE)-- Schrödinger (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference. The pre-recorded presentation will be available on Thursday, November 18, 2021, after 8:00 a.m. GMT / 3:00 a.m. ET.
The “on demand” webcast can be accessed under "News & Events" in the investors section of Schrödinger’s website, https://ir.schrodinger.com/news-and-events/event-calendar and will be archived for approximately 14 days.
About Schrödinger
Schrödinger is transforming the way therapeutics and materials are discovered. Schrödinger has pioneered a physics-based software platform that enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at lower cost compared to traditional methods. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Schrödinger’s multidisciplinary drug discovery team also leverages the software platform to advance collaborative programs and its own pipeline of novel therapeutics to address unmet medical needs.
Founded in 1990, Schrödinger has over 500 employees and is engaged with customers and collaborators in more than 70 countries. To learn more, visit www.schrodinger.com and follow us on LinkedIn and Twitter.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211109005416/en/
Jaren Irene Madden
Schrödinger, Inc.
[email protected]
617-286-6264
Tracy Lessor
Schrödinger, Inc.
[email protected]
617-519-9827
Source: Schrödinger
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Japan Maritime Daily to Host International Shipping Seminar in Singapore on October 5, 2026
- INNMI Peptide Continues to Expand Peptide Product Portfolio, Strengthening Global Market Reach and Production Service Capabilities
- Asahi Kasei Develops Novel Lithium Pre-doping Technology to Raise Energy Density and Lower Cost of Silicon-rich Lithium-ion Batteries
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
Jefferies & Co, TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share